The drug is obicetrapib, a next-generation oral CETP inhibitor developed by NewAmsterdam Pharma, and it does something no widely available cholesterol medication has managed to do well: raise HDL cholesterol by roughly 140 percent while simultaneously lowering LDL by 33 to 36 percent. For anyone tracking the connection between cardiovascular health and long-term brain function, this is worth paying attention to. Poor cholesterol profiles don’t just clog arteries feeding the heart — they starve the brain of blood flow, and mounting research ties midlife cardiovascular risk factors to later cognitive decline and dementia. Obicetrapib isn’t approved yet.
The European Medicines Agency has accepted NewAmsterdam’s marketing authorization application for review, with regulatory decisions expected in the second half of 2026. The pivotal PREVAIL cardiovascular outcomes trial, which enrolled 9,541 patients, should deliver results around the same time. But the Phase 3 data published in the New England Journal of Medicine is striking enough that neurologists and cardiologists alike are watching closely. This article covers what obicetrapib actually does and how it differs from every cholesterol drug currently on the market, the troubled history of drugs that tried and failed to raise HDL before it, what existing medications can and cannot do for your HDL levels, and why all of this matters for your brain — not just your heart.
Table of Contents
- What Is the Cholesterol Drug That Raises HDL and Lowers LDL at the Same Time?
- Why Did Earlier HDL-Raising Drugs Fail — and Why Might This One Be Different?
- The HDL Hypothesis and What It Means for Brain Health
- What Currently Available Drugs Do to HDL — and Their Tradeoffs
- Limitations and Warnings About Chasing HDL Numbers
- The Financial and Regulatory Picture for Obicetrapib
- What the PREVAIL Trial Could Mean for the Future of Cholesterol Treatment and Brain Health
- Conclusion
- Frequently Asked Questions
What Is the Cholesterol Drug That Raises HDL and Lowers LDL at the Same Time?
Obicetrapib works by blocking cholesteryl ester transfer protein, or CETP — a molecule that shuttles cholesterol from HDL particles to LDL particles. Block that transfer, and HDL levels climb while LDL drops. In Phase 3 trials called BROOKLYN and BROADWAY, patients taking obicetrapib saw their HDL cholesterol jump by approximately 140 percent compared to placebo, going from baseline levels to an average increase of 68 mg/dL versus just 1 mg/dL for the placebo group. At the same time, LDL cholesterol fell by 33 to 36 percent. When combined with ezetimibe in the TANDEM trial, LDL reductions reached roughly 49 percent. The drug also hits two other markers that cardiologists care about.
It reduces lipoprotein(a) — a genetically determined risk factor that no statin touches effectively — by about 37 percent, and it lowers apolipoprotein B by around 25 percent. Apolipoprotein B is considered by many researchers to be a better predictor of cardiovascular risk than LDL alone. That triple action — HDL up, LDL down, Lp(a) down — is what separates obicetrapib from anything currently available by prescription. But here’s the critical caveat: raising HDL numbers on a lab report does not automatically prevent heart attacks or strokes. That question remains unanswered until the PREVAIL trial reports out. The history of drugs that raised HDL without improving outcomes is long and expensive, and anyone who tells you obicetrapib is a guaranteed breakthrough before those results come in is getting ahead of the evidence.
Why Did Earlier HDL-Raising Drugs Fail — and Why Might This One Be Different?
Obicetrapib is not the first CETP inhibitor. It is the fifth. The four that came before it represent one of the most costly sequences of clinical failures in pharmaceutical history, and understanding those failures is essential context for evaluating the current drug. Pfizer’s torcetrapib was terminated at the end of 2006 after it actually increased cardiovascular events and mortality — it raised HDL, but it also raised blood pressure through off-target effects, and patients died. Roche’s dalcetrapib was killed in late 2012 for futility; it raised HDL modestly but did nothing to reduce recurrent cardiovascular events. Eli Lilly’s evacetrapib followed in late 2015 with the same result — robust HDL increases, zero reduction in the composite cardiovascular endpoint. The one partial success was Merck’s anacetrapib.
The massive REVEAL trial showed that anacetrapib did reduce coronary heart disease events when added to statin therapy. But the effect was modest, the drug accumulated in fatty tissue for years after patients stopped taking it, and Merck ultimately decided not to pursue FDA approval. That decision left the entire CETP inhibitor class for dead. What changed with obicetrapib is selectivity. NewAmsterdam Pharma designed the molecule to inhibit CETP more potently at a much lower dose, which appears to avoid the off-target toxicity that destroyed torcetrapib and the weak efficacy that sank dalcetrapib. However, if the PREVAIL outcomes trial does not show a reduction in cardiovascular events, the drug’s commercial future — and the entire HDL-raising hypothesis — will be in serious trouble regardless of how impressive the lipid numbers look. Lab values are not the same as living longer.
The HDL Hypothesis and What It Means for Brain Health
The idea that raising HDL prevents disease — known as the “HDL hypothesis” — has been largely called into question over the past decade. The niacin trials were the turning point. Two large studies, AIM-HIGH and HPS2-THRIVE, tested whether adding prescription niacin to statin therapy would reduce cardiovascular events. Niacin reliably raises HDL and lowers triglycerides. But in both trials, patients taking niacin fared no better than those on placebo, and they experienced significantly more side effects. The medical community took this as strong evidence that simply pushing the HDL number higher is not enough. For dementia researchers, though, the story is more nuanced.
The brain depends on an intact vascular system — it consumes roughly 20 percent of the body’s oxygen supply delivered through blood vessels. Atherosclerosis in the carotid arteries and the brain’s smaller vessels directly reduces blood flow to neurons. HDL particles do more than just carry cholesterol in reverse transport; they have anti-inflammatory and antioxidant properties that may protect the blood-brain barrier. Some observational studies have linked higher HDL levels in midlife with lower dementia risk decades later, though observational data cannot prove causation. The question that matters is whether a drug like obicetrapib, which dramatically raises HDL while also lowering LDL and lipoprotein(a), might do for brain vasculature what we hope it does for coronary arteries. That is speculative right now. The PREVAIL trial is measuring cardiovascular endpoints, not cognitive ones. But if the cardiovascular results are positive, it would almost certainly trigger interest in studying the drug’s effects on vascular dementia and Alzheimer’s disease risk — conditions where cerebrovascular health plays an established role.
What Currently Available Drugs Do to HDL — and Their Tradeoffs
If you or a family member is trying to improve HDL levels today, without waiting for obicetrapib’s approval, the options are limited and come with real tradeoffs. Statins are the most widely prescribed cholesterol drugs in the world, but their effect on HDL is modest at best — typically raising it by 3 to 15 percent depending on the specific statin and dose. Rosuvastatin at 10 mg raises HDL by roughly 9.5 percent. Pitavastatin appears to raise HDL to a somewhat greater extent than other statins and does so progressively over time, which has made it a point of interest for clinicians who care about the HDL side of the equation. Fibrates — gemfibrozil (brand name Lopid) and fenofibrate — have a considerably greater effect on HDL than statins do, and they also lower triglycerides significantly.
They are sometimes prescribed alongside a statin for patients with the combination of low HDL and high triglycerides, though the combination raises the risk of muscle-related side effects. For someone whose primary problem is low HDL with high triglycerides rather than elevated LDL, fibrates may be more directly relevant than statins alone. Prescription niacin remains technically available, but after the AIM-HIGH and HPS2-THRIVE failures, very few cardiologists prescribe it with enthusiasm. It raises HDL and lowers triglycerides on paper, but it did not reduce heart attacks or strokes in those trials, and the side effect profile — flushing, liver toxicity, glucose elevation — makes it a tough sell. The comparison to obicetrapib’s 140 percent HDL increase is almost absurd in scale, but again, what matters clinically is not the number on the lab slip but whether patients actually have fewer events.
Limitations and Warnings About Chasing HDL Numbers
One of the most important things to understand about HDL cholesterol is that not all HDL particles are equal, and a higher number does not always mean better function. Researchers have increasingly distinguished between HDL quantity — what your blood test measures — and HDL functionality, meaning how well those particles actually perform reverse cholesterol transport, reduce inflammation, and protect the vascular endothelium. Some genetic variants that raise HDL to very high levels do not appear to protect against heart disease at all. This is why the failed CETP inhibitor history is so instructive. Dalcetrapib raised HDL substantially, yet patients saw zero benefit.
The emerging theory is that dalcetrapib created HDL particles that were large but functionally impaired — essentially cholesterol-stuffed balloons that looked good on a lab report but did not do the biological work that makes HDL protective. Whether obicetrapib creates functionally superior HDL particles is an area of active research, but there is no definitive answer yet. For patients and caregivers in the dementia space, the practical warning is this: do not fixate on a single lab value. A person’s cardiovascular and cerebrovascular risk depends on the interaction of LDL, HDL, triglycerides, lipoprotein(a), blood pressure, blood sugar, inflammation, and dozens of other factors. Raising HDL through exercise, moderate alcohol consumption, or medication is potentially helpful, but it is not a silver bullet for preventing cognitive decline. Any clinician who suggests otherwise is oversimplifying the science.
The Financial and Regulatory Picture for Obicetrapib
NewAmsterdam Pharma is not a major pharmaceutical company — it is a relatively small, focused biotech that has bet essentially everything on obicetrapib. As of December 31, 2025, the company held $728.9 million in cash, which it says is sufficient to fund operations through the PREVAIL trial readout and a potential U.S. commercial launch. The EMA, along with regulators in the UK and Switzerland, are expected to make approval decisions in the second half of 2026.
No FDA application has been filed yet, meaning U.S. availability — if it happens — is further out. For families dealing with dementia or cognitive decline today, this means obicetrapib is not something you can ask a doctor to prescribe. It is a drug to watch, not a drug to take. If the PREVAIL results are positive and regulatory approvals follow, it could become available in Europe before the United States, which is an unusual sequence for a major cardiovascular drug.
What the PREVAIL Trial Could Mean for the Future of Cholesterol Treatment and Brain Health
The PREVAIL cardiovascular outcomes trial enrolled 9,541 patients and completed enrollment in April 2024, with results expected in late 2026. This trial is the single most important piece of evidence that will determine whether obicetrapib changes clinical practice or joins the graveyard of promising HDL drugs. If PREVAIL shows a statistically significant reduction in major cardiovascular events — heart attacks, strokes, cardiovascular death — it would validate not just this specific drug but the broader concept that CETP inhibition can work when done correctly. The downstream implications for brain health could be substantial.
Stroke prevention is dementia prevention — every stroke, including silent ones that patients never notice, damages brain tissue and increases the risk of vascular cognitive impairment. A drug that reduces stroke incidence while improving the overall lipid profile would immediately enter the conversation about neuroprotective strategies. But we are not there yet. Late 2026 will bring either a genuine shift in how we think about cholesterol management and brain protection, or another expensive lesson in the difference between moving lab numbers and actually keeping people healthy.
Conclusion
Obicetrapib represents the most significant attempt in over a decade to prove that raising HDL cholesterol — when combined with meaningful LDL and lipoprotein(a) reduction — can prevent cardiovascular events. Its Phase 3 data showing a 140 percent increase in HDL alongside a 33 to 36 percent reduction in LDL is unlike anything currently available, and its publication in the New England Journal of Medicine signals that the scientific community is taking it seriously. For people concerned about brain health and dementia prevention, the cardiovascular-cerebrovascular connection makes this drug especially relevant, since the same arterial damage that causes heart attacks also starves the brain of the blood flow it needs to function.
Until the PREVAIL trial results arrive in late 2026, the honest position is cautious optimism. The history of CETP inhibitors is a history of spectacular failures, and the drug that finally works will need to clear a high evidentiary bar. In the meantime, the best available strategies for protecting both heart and brain remain the unsexy ones: managing LDL with statins or other proven therapies, controlling blood pressure, exercising, and staying engaged in the ongoing conversation with your doctor about what your specific risk factors require.
Frequently Asked Questions
What is obicetrapib and how does it work?
Obicetrapib is an oral CETP inhibitor that blocks the protein responsible for transferring cholesterol from HDL particles to LDL particles. By inhibiting this transfer, it raises HDL cholesterol by approximately 140 percent while lowering LDL by 33 to 36 percent. It is not yet approved by any regulatory agency.
Can I get obicetrapib prescribed today?
No. Obicetrapib is still in clinical trials. The EMA is reviewing a marketing authorization application with a decision expected in the second half of 2026. No FDA application has been filed in the United States. It is not available by prescription anywhere in the world as of early 2026.
Why did previous HDL-raising drugs fail?
Four earlier CETP inhibitors failed for different reasons. Torcetrapib caused dangerous off-target effects including increased blood pressure and mortality. Dalcetrapib and evacetrapib simply did not reduce cardiovascular events despite raising HDL. Anacetrapib showed modest benefit but accumulated in body fat, and Merck chose not to seek approval.
Does raising HDL cholesterol protect against dementia?
Some observational studies have linked higher midlife HDL levels with lower dementia risk, but no drug trial has proven that pharmacologically raising HDL prevents cognitive decline. HDL particles have anti-inflammatory properties that may protect brain vasculature, but this remains an area of active research rather than established fact.
What drugs currently available can raise HDL?
Statins raise HDL modestly by 3 to 15 percent, with pitavastatin showing the largest effect among statins. Fibrates like gemfibrozil and fenofibrate have a considerably greater effect on HDL than statins. Prescription niacin raises HDL but failed to reduce cardiovascular events in two major trials and carries significant side effects.
When will we know if obicetrapib actually prevents heart attacks and strokes?
The PREVAIL cardiovascular outcomes trial, which enrolled 9,541 patients, is expected to report results in late 2026. This trial will be the definitive test of whether obicetrapib’s dramatic lipid changes translate into fewer cardiovascular events.
